PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Ryan, Charles J.
TI  - Abiraterone Significantly Extends Survival in mCRPC
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 16--17
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/16.short
4100  - http://mdc.sagepub.com/content/14/36/16.full
AB  - Abiraterone acetate as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival (OS) compared with placebo in the final OS analysis of the phase 3 COU-AA-302 clinical trial. This article discusses data from more than 4 years of follow-up from the international, randomized, double-blind, placebo-controlled COU-AA-302. Abiraterone is an orally available inhibitor of the CYP17 enzyme complex, a key regulator of androgen synthesis.